Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions. The Company primarily provides Cytori Cell Therapy for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets, and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The Company also provides a number of products for use in treating various cancers.

Employee Rating

2.9More
TypePublic
HQSan Diego, US
Founded2002
Size (employees)80 (est)
Websitecytori.com
Cytori Therapeutics was founded in 2002 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cytori Therapeutics

John K. Fraser

John K. Fraser

Chief Scientist
Marc H. Hedrick

Marc H. Hedrick

President/CEO
Gregg A Lapointe

Gregg A Lapointe

Director
Gary A. Lyons

Gary A. Lyons

Director
Ronald A. Martell

Ronald A. Martell

Director
Richard J. Hawkins

Richard J. Hawkins

Chairman
Show more

Cytori Therapeutics Office Locations

Cytori Therapeutics has offices in San Diego, San Antonio, Tokyo and Deeside
San Diego, (HQ)
3020 Callan Road
San Antonio,
12500 Network Blvd
Tokyo,
Otemachi Park Building 7F 1-1-1 Otemachi, Chiyoda-ku
Deeside,
Deeside Industrial Park East Unit 68, Third Avenue
Show all (4)
Report incorrect company information

Cytori Therapeutics Financials and Metrics

Cytori Therapeutics Revenue

Cytori Therapeutics's revenue was reported to be $4.66 m in FY, 2016 which is a 3.8% decrease from the previous period.
USD

Net income (Q3, 2018)

(2.3m)

EBIT (Q3, 2018)

(1.5m)

Market capitalization (16-Aug-2018)

194.3k

Closing stock price (16-Aug-2018)

0.3

Cash (30-Sep-2018)

6.8m
Cytori Therapeutics's current market capitalization is $194.3 k.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.1m5.0m4.8m4.7m

Revenue growth, %

(30%)(2%)(4%)

Cost of goods sold

3.4m2.9m3.2m2.7m

Gross profit

3.7m2.0m1.7m1.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Sales and marketing expense

1.8m1.9m1.9m1.5m654.0k566.0k1.0m889.0k818.0k939.0k1.3m840.0k678.0k525.0k453.0k

General and administrative expense

4.3m4.3m4.6m4.2m2.8m2.4m2.3m2.3m2.0m2.1m2.1m1.8m2.2m1.5m1.5m

R&D expense

4.1m4.3m4.7m3.1m6.0m4.4m4.1m5.2m4.0m3.3m3.0m3.0m2.5m2.0m1.9m

Operating expense total

10.2m10.6m11.2m8.7m(3.6m)(22.0k)7.4m8.5m6.8m8.0m6.4m5.6m5.4m3.9m2.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

15.5m14.6m14.3m12.6m9.6m

Accounts Receivable

Inventories

3.7m4.3m3.7m3.2m

Current Assets

24.6m21.7m21.2m18.7m14.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.2m)(37.4m)(18.7m)(22.0m)(22.7m)

Depreciation and Amortization

1.6m779.0k1.1m1.2m2.2m

Inventories

(459.0k)(815.0k)490.0k471.0k251.0k

Accounts Payable

(409.0k)(1.1m)1.0m(673.0k)(1.8m)
USDY, 2018

Financial Leverage

4.2 x
Show all financial metrics
Report incorrect company information

Cytori Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Cytori Therapeutics News and Updates

Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone

SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divest…

Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Presentation on Thursday, September 06, 2018 at 09:10 AM Eastern Time Presentation on Thursday, September 06, 2018 at 09:10 AM Eastern Time
Report incorrect company information

Cytori Therapeutics Company Life and Culture

Report incorrect company information

Cytori Therapeutics Frequently Asked Questions

  • When was Cytori Therapeutics founded?

    Cytori Therapeutics was founded in 2002.

  • Who are Cytori Therapeutics key executives?

    Cytori Therapeutics's key executives are John K. Fraser, Marc H. Hedrick and Gregg A Lapointe.

  • How many employees does Cytori Therapeutics have?

    Cytori Therapeutics has 80 employees.

  • Who are Cytori Therapeutics competitors?

    Competitors of Cytori Therapeutics include Sareum Holdings, ImmunoCellular Therapeutics and Seres Therapeutics.

  • Where is Cytori Therapeutics headquarters?

    Cytori Therapeutics headquarters is located at 3020 Callan Road , San Diego.

  • Where are Cytori Therapeutics offices?

    Cytori Therapeutics has offices in San Diego, San Antonio, Tokyo and Deeside.

  • How many offices does Cytori Therapeutics have?

    Cytori Therapeutics has 4 offices.